Fair comment. However there will come a time when a line needs to be drawn. Nothing alters the fact that a massive amount of capital is required to develop a vaccine / drug.Building a stake in Admedus vaccines is not a positive if it doesn't succeed. We are just financing research.
My belief is the company would thrive without the vaccine.
Previously I have suggested creating a separate company listing for the vaccine. This allows investors to decide whether they want to finance research ,or support a growing company. They also have the opportunity to do both.
any reason for share price wilting?, page-10
-
- There are more pages in this discussion • 32 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add AVR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$12.22 |
Change
0.740(6.45%) |
Mkt cap ! $258.3M | |||
| Open | High | Low | Value | Volume |
| $11.50 | $12.25 | $11.49 | $395.2K | 33.29K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 100 | $11.70 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $12.22 | 127 | 1 |
View Market Depth
| Last trade - 16.10pm 18/10/2024 (20 minute delay) ? |
| AVR (ASX) Chart |